Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1

Status

Completed 2Withdrawn 1Unknown 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1Breast 1

Conditions

Somatoform Disorders 1Prostatic Neoplasms 1Peripheral Nervous System Diseases 1Breast Neoplasms 1

Interventions

Cyclophosphamide 741Cisplatin 688Gemcitabine 641Bevacizumab 616Carboplatin 605Paclitaxel 601Docetaxel 565Radiotherapy 536Fluorouracil 405Oxaliplatin 387Rituximab 369Doxorubicin 361Capecitabine 342Filgrastim 333Etoposide 330Dexamethasone 312Irinotecan 309pembrolizumab 282Leucovorin 274Cetuximab 268Cytarabine 242Erlotinib Hydrochloride 231Nivolumab 228Prednisone 227Trastuzumab 225Vincristine 221Bortezomib 221Methotrexate 207Pemetrexed 199fludarabine phosphate 195

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Completed × Etoricoxib × Clear all
NCT04565600 2022-02-14

Prevention of Taxane-associated Acute Pain Syndrome With Etoricoxib

Guangdong Provincial People's Hospital

Phase 2 Completed
144 enrolled
Breast

Breast Neoplasms, Peripheral Nervous System Diseases, Somatoform Disorders

NCT00427999 2016-11-21

INV342

Novartis

Phase 2 Completed
67 enrolled 6 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡